Source - SMW
ReNeuron Group said that positive long-term clinical trial data for a stroke disability treatment was accepted for a podium presentation yesterday at the American Heart Association International Stroke Conference in Los Angeles.

The company recently announced positive top-line long-term data from the clinical trial in which response rates in key measures reported at three months after treatment were sustained at 12 months post-treatment.




Related Charts

ReNeuron Group (RENE)

+4.50p (+4.86%)
delayed 16:55PM